Drug Type AAV based gene therapy |
Synonyms- |
Target |
Mechanism ATXN2 inhibitors(ataxin 2 inhibitors) |
Active Indication |
Inactive Indication- |
Originator Organization Affinia Therapeutics, Inc.Startup |
Active Organization Affinia Therapeutics, Inc.Startup |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Amyotrophic Lateral Sclerosis | Preclinical | US | Affinia Therapeutics, Inc.Startup | 10 May 2024 |